How Many People Have Insomnia? Global and US Statistics

Insomnia is the most common sleep disorder in the world. Depending on how it's measured, roughly 30–40% of adults experience insomnia symptoms in any given year, and about 10% live with chronic insomnia disorder — a clinical condition defined by sleep difficulty at least three nights a week for three months or longer. Women, adults over 65, shift workers, and people with mood disorders carry the highest burden. Here is the full data picture, with sources.

Global Prevalence

A single global number is hard to pin down because national surveys use different definitions and recall windows. The most-cited synthesis, the 2022 Sleep Medicine Reviews meta-analysis led by Charles Morin, pooled 50+ countries and landed on roughly 30% of adults reporting insomnia symptoms and 10% meeting DSM-5 or ICSD-3 criteria for insomnia disorder.

Country variation is striking. The US, France, and Japan all sit at the top of the range (32–38% for any symptoms). Mainland China reports lower rates but shows worse objective sleep in polysomnography studies. Developing regions show reported prevalence of 15–25%, which sleep researchers broadly agree underreports reality due to limited access to care and weaker epidemiological surveillance.

A 2023 Lancet commentary put it bluntly: global burden is almost certainly higher than any dataset captures, because roughly two-thirds of people meeting clinical criteria never raise it with a clinician.

United States Data

US insomnia data is the best-instrumented in the world, anchored by the CDC's BRFSS and NHIS, the NHANES exam-plus-interview cohort, and the NSF's Sleep in America poll. The most-cited figure — that about 70 million Americans live with a chronic sleep problem — comes from the CDC. Of those, roughly 50–70 million report insomnia symptoms and an estimated 25–30 million meet chronic insomnia disorder criteria. More than 1 in 10 US adults have insomnia severe enough to impair daytime functioning.

One nuance: CDC flags symptoms on any "yes" to trouble falling or staying asleep on 3+ days last week. That broad net is why "any symptoms" runs so much higher than the clinical-disorder number — both matter, but they measure different things.

Prevalence by Age Group

The sharpest pattern in the literature is a steady climb from young adulthood into late life, with a steep jump after 65.

• Children & teens (5–17): 10–25% report persistent sleep difficulty. Pediatric insomnia is broadly undertreated.
• Young adults (18–34): 18–22% symptoms; chronic disorder only 6–8%. Tied to stress, irregular schedules, screen exposure.
• Middle age (35–54): 30–35% symptoms, 9–11% chronic. Career stress, caregiving, perimenopause, cardiometabolic issues.
• Pre-senior (55–64): 35–45% symptoms. Menopause and early cardiovascular comorbidities dominate.
• Seniors (65+): 50–60% symptoms, 15–20% chronic. Reduced slow-wave sleep, medications, pain, nocturia.

Our insomnia after 50 guide unpacks the hormonal, architectural, and medication drivers in detail.

Prevalence by Gender

Across essentially every national survey, women are about 1.4× more likely than men to experience insomnia. The gap opens in adolescence, peaks in middle adulthood, and narrows after age 70 — men catch up partly because of nocturia and rising cardiovascular burden.

Well-documented drivers of the female excess risk:

• Luteal-phase effects: increased fragmentation and reduced sleep efficiency in women with PMS.
• Pregnancy: 75–80% of pregnant women report symptoms, peaking in the third trimester.
• Perimenopause and menopause: hot flashes and night sweats trigger insomnia; complaints peak perimenopausally and partially remit after estrogen stabilizes.
• Mood-disorder comorbidity: women have ~2× lifetime prevalence of depression and anxiety, both bidirectional with insomnia.

Men almost certainly underreport. NSF polls with a help-seeking question consistently find men less likely to label their sleep a problem even when objective metrics match affected women.

Prevalence by Socioeconomic Status

Lower SES is one of the most robust predictors of insomnia in US epidemiology, operating through several compounding mechanisms.

• Income gradient: lowest quintile adults report insomnia at ~1.5× the rate of the highest quintile, visible across race, age, and region.
• Shift-work overrepresentation: 15–20% of the US workforce is in non-standard shifts (healthcare, manufacturing, logistics, service); shift-work sleep disorder affects 60–80% of this group.
• Financial stress: adults who "often or always worry about money" are 2–3× more likely to report insomnia per NSF polls.
• Housing quality: noise, temperature variability, and crowded sleep environments cluster with lower income.

Insomnia compounds other SES-related health risks (cardiometabolic disease, depression, accidents) rather than sitting alongside them independently.

Race and Ethnicity

US data consistently show disparities in insomnia prevalence and, even more starkly, in access to evidence-based treatment.

• Black Americans report comparable or higher symptom rates than White Americans, and show worse objective metrics in polysomnography. Access to sleep specialists is roughly half the rate of White counterparts.
• Hispanic/Latino Americans report modestly higher symptom rates; language barriers and uninsured rates limit CBT-I access.
• Asian Americans show lower reported insomnia; cultural stigma likely suppresses rates.
• Native American and Alaska Native populations show the highest reported rates in some CDC datasets (40%+), driven by compounding health and access factors.

Burden is not evenly distributed, and policy conversations too often center the demographic closest to the average instead of the worst-affected.

Chronic vs Acute Insomnia Rates

The literature splits insomnia into three severity tiers:

• Acute / transient (<3 months): ~30–40% of US adults annually. Triggered by specific life stressors; usually resolves in days to weeks.
• Chronic insomnia disorder (≥3 months, ≥3 nights/week): ~10% of US adults. The clinically recognized condition requiring structured treatment.
• Severe / disabling (significant daytime impairment): 3–4% of US adults. Most likely to involve hypnotics and repeated clinical visits.

Longitudinal studies show only ~15–20% of acute episodes progress to chronic disorder. The transition is driven less by the initial trigger than by downstream behaviors (more time in bed, daytime napping, alcohol as a sleep aid) that condition the brain to associate the bed with wakefulness.

Post-Pandemic Shifts: The Coronasomnia Effect

COVID produced the largest short-term shift in recorded insomnia epidemiology. A 2021 meta-analysis of 44 studies found global insomnia prevalence rose from roughly 18% to 27% during peak 2020–21 lockdown. Healthcare workers were hit hardest: ~40% developed clinically significant insomnia per BMJ Open.

• Acute lockdown insomnia: driven by anxiety, disrupted routines, and reduced natural light. Mostly resolved by 2022–23.
• Long COVID sleep sequelae: ~35% of long COVID patients report persistent sleep disturbance 6+ months after infection.
• Remote work: mixed. Eliminated commutes helped duration; screen time and boundary erosion hurt quality.

By 2026, US insomnia prevalence has partially retreated but sits several percentage points above 2019 — a new, elevated baseline.

Economic Impact

A RAND analysis estimates insufficient sleep costs the US economy roughly $411 billion a year, with insomnia specifically contributing a large share. Earlier Sleep-journal work by Daley et al. (2009) pegged direct-plus-indirect insomnia costs at $63–100 billion annually; updated estimates put the figure above $100 billion in 2020s dollars.

• Lost productivity: the largest bucket — presenteeism (impaired at work) outweighs absenteeism by 3–4×.
• Healthcare utilization: 5.5 million annual primary-care visits name insomnia, plus specialist referrals and sleep studies.
• Accidents: CDC attributes 6,000+ fatal motor vehicle crashes annually to drowsy driving.
• Downstream chronic disease: cardiovascular disease, type 2 diabetes, and depression all carry their own cost tails.

Comorbidities: The Bidirectional Web

About 90% of chronic insomnia cases are comorbid with at least one other condition, and the relationships are almost always bidirectional.

• Depression: 75–90% of MDD patients report insomnia; insomnia roughly doubles 12-month depression risk. Treating insomnia alone improves depressive symptoms.
• Anxiety disorders: GAD, PTSD, and panic all show 70%+ comorbidity. The worry → poor sleep → more worry loop is the clinical signature.
• Cardiovascular disease: chronic insomnia is associated with ~45% higher relative coronary heart disease risk and elevated stroke risk.
• Type 2 diabetes: short sleep and insomnia both impair glucose regulation; the association is bidirectional.
• Obesity: poor sleep disrupts leptin/ghrelin signaling; sleep apnea feeds back into insomnia.
• Chronic pain: 50–80% comorbidity. Pain disrupts sleep; poor sleep lowers pain thresholds.

Modern AASM guidelines emphasize treating insomnia alongside comorbid conditions rather than assuming it resolves when the partner is addressed.

Trends Over Time

Longitudinal data from NHANES, BRFSS, and comparable surveys show a clear upward trend since the late 1990s.

Screen time is the most-studied candidate driver. NSF and NHANES data show a dose-response between evening screen exposure and insomnia, especially in adolescents. Interventional studies (blue-light blocking, device curfews) show improvements consistent with a causal role.

Data Sources and Reliability

Most insomnia statistics you'll see online trace to one of these sources:

• CDC BRFSS: annual state-level phone survey, n > 400,000. Best for geographic and demographic breakdowns.
• CDC NHIS: annual household survey, n ~ 30,000. Captures healthcare utilization in detail.
• NHANES: the gold standard — interviews plus physical exams and (some waves) actigraphy.
• NSF Sleep in America poll: good for trends and attitudes; less rigorous on prevalence.
• AASM clinical registries: capture diagnosed insomnia only — best for severity and treatment data.
• DSM-5 and ICSD-3: the two diagnostic frameworks. ICSD-3 is preferred by sleep specialists.

Where figures disagree, it's usually because definitions differ. A "30% prevalence" headline can mean one-time acute symptoms, recurrent symptoms, or full disorder criteria — three groups that don't overlap cleanly.

The Treatment Gap

The most underdiscussed statistic: only ~30% of people with chronic insomnia ever seek professional care. Of those who do, fewer than half receive the AASM-recommended first line (CBT-I).

• CBT-I access: ~700 behavioral sleep medicine specialists in the US vs 25M+ chronic insomnia patients.
• Digital CBT-I: apps like Somryst (FDA-authorized) and Sleepio have expanded access — see our sleep aid apps guide.
• Polypharmacy rise: US hypnotic prescriptions doubled 2000–2020; benzo+hypnotic combos remain common despite guideline warnings.
• Melatonin boom: sales tripled during the pandemic. See our melatonin guide.
• Middle path: supplements like NooCube Sleep, magnesium, and L-theanine occupy the space between "do nothing" and "prescription hypnotic."

For structured self-help, see our insomnia tips and insomnia causes guides. For pharmacological options, our sleep medication overview and natural sleep aids comparison are the best starting points.

What This Means for You

Statistics are population abstractions. The real question is "where do I fit?"

• 30–40% with occasional symptoms: common, typically transient, usually responsive to basic sleep hygiene, environmental fixes, and a short course of magnesium or a melatonin-free aid. You probably don't need a specialist.
• 10% with chronic insomnia (3+ nights/week, 3+ months): consider digital CBT-I (Somryst / Sleepio) or ask for a sleep medicine referral. Chronic insomnia rarely resolves on its own.
• 3–4% with severe, disabling insomnia: don't stay stuck in the OTC cycle. A sleep specialist can rule out apnea, restless legs, and circadian disorders that masquerade as plain insomnia.
• Over 50 with emerging issues: the rules shift — medications, hormones, and architecture matter more. See our insomnia after 50 guide.

You're almost certainly not alone, and the toolkit — CBT-I apps, melatonin-free supplements, environmental fixes — is broader and more evidence-backed than most people realize.

FAQ

Is insomnia more common now than it used to be?
Yes. Global meta-analyses show prevalence rising from about 17% pre-2000 to roughly 30–33% in 2023–26. The pandemic pushed it higher briefly, and the post-pandemic baseline remains elevated above 2019.

Is insomnia genetic?
Partly. Twin studies estimate heritability at 30–40% — meaningful but far from deterministic. Known risk genes cluster around circadian regulation (CLOCK, PER3) and serotonergic signaling. Most of the prevalence variance is driven by environment and behavior, not genetics.

Why does insomnia get worse after age 50?
A combination of menopausal or andropausal hormonal shifts, age-related reduction in slow-wave sleep, more frequent bathroom trips, medication side effects, chronic pain accumulation, and cardiovascular comorbidity. See insomnia after 50 for the full breakdown.

Is insomnia more common in rural or urban areas?
BRFSS data shows modestly higher prevalence in urban and deep-rural areas than in suburban. Urban factors are noise, light pollution, and stress; rural factors are access to care and shift-work patterns.

Who is most at risk of chronic insomnia?
Women, adults over 65, shift workers, people with anxiety or depression, people with chronic pain, and people in the lowest income quintile are the five consistent high-prevalence groups.

How common is insomnia in children?
Roughly 10–25% of children and teens report persistent sleep difficulty. Pediatric insomnia is broadly undertreated because parents often don't frame it as a medical issue.

Which country has the highest insomnia rate?
Comparisons are tricky due to definition differences, but the US, France, and Japan consistently land in the upper tier of reported rates. Latin American countries often report the highest prevalence when measured with equivalent tools.

How is insomnia diagnosed?
Primarily clinical interview — there's no blood test. DSM-5 and ICSD-3 criteria require difficulty initiating or maintaining sleep at least three nights a week for three months, with meaningful daytime impairment. Sleep diaries and validated questionnaires (ISI, PSQI) support the diagnosis; polysomnography is used mostly to rule out other sleep disorders.

When is insomnia concerning enough to see a doctor?
If sleep difficulty has persisted at least three nights a week for three months, is affecting your daytime functioning, is prompting you to use alcohol or OTC sleep aids regularly, or is associated with depression, anxiety, or suicidal thinking — see a clinician. Don't wait longer than 6 months for chronic issues.

Related reading: NooCube Sleep Upgrade review | Insomnia tips | Insomnia causes | Insomnia after 50 | CBT-I sleep guide | Melatonin for sleep | Sleep aid apps | Sleep medication overview | Natural sleep aids